

POLICY Document for NEULASTA ONPRO

The overall objective of this policy is to support the appropriate and cost-effective use of the medication, specific to use of preferred medication options, and overall, clinically appropriate use. This document provides specific information to both sections of the overall policy.

Section 1: Preferred Product

- Policy information specific to preferred medications

Section 2: Clinical Criteria

- Policy information specific to the clinical appropriateness for the medication

Section 1: Preferred Product

CAREFIRST: EXCEPTIONS CRITERIA Colony Stimulating Factors – Long Acting

PREFERRED PRODUCTS: FULPHILA, UDENYCA (INCLUDING ON-BODY INJECTOR)

Client Requested: The intent of the criteria is to ensure that patients follow selection elements as established by CareFirst.

POLICY

This policy informs prescribers of preferred products and provides an exception process for targeted products through prior authorization.

I. PLAN DESIGN SUMMARY

This program applies to the long-acting colony stimulating factor products specified in this policy. Coverage for targeted product is provided based on clinical circumstances that would exclude the use of the preferred products and may be based on previous use of a product. The coverage review process will ascertain situations where a clinical exception can be made. This program applies to all members requesting treatment with a targeted product.

Each referral is reviewed based on all utilization management (UM) programs implemented for the client.

Table. Colony Stimulating Factors – Long Acting

	Product(s)
Preferred*	• Fulphila (pegfilgrastim-jmdb) • Udenyca (including On-body injector) (pegfilgrastim-cbqv)
Targeted	• Fylnetra (pegfilgrastim-pbbk) • Neulasta (including Onpro kit) (pegfilgrastim) • Nyvepria (pegfilgrastim-apgf) • Rolvedon (eflapeggrastim-xnst) • Stimufend (pegfilgrastim-fpgk) • Ziextenzo (pegfilgrastim-bmez)

I. EXCEPTION CRITERIA

This program applies to members requesting treatment for an indication that is FDA-approved for the preferred products.

Coverage for a targeted product is provided when the following criteria is met:

- A. For Neulasta, when the member is a pediatric patient weighing less than 45 kg and utilizing the 4 mg/0.4 mL vials.
- B. For all other products:
 - 1. Member has a documented inadequate response, contraindication, or intolerable adverse event to all preferred products and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information (i.e., known adverse reaction for both the reference product and biosimilar products).

Section 2: Clinical Criteria

Specialty Guideline Management

Neulasta and pegfilgrastim biosimilars

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Neulasta	pegfilgrastim
Armlupeg	pegfilgrastim-unne
Ennumo	pegfilgrastim-pccg
Fulphila	pegfilgrastim-jmdb
Fylnetra	pegfilgrastim-pbbk
Nyvepria	pegfilgrastim-apgf
Stimufend	pegfilgrastim-fpgk
Udenyca	pegfilgrastim-cbqv
Ziextenzo	pegfilgrastim-bmez

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications

Neulasta¹

Patients with Cancer Receiving Myelosuppressive Chemotherapy

Neulasta is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Hematopoietic Subsyndrome of Acute Radiation Syndrome

Neulasta is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).

Armlupeg²

Patients with Cancer Receiving Myelosuppressive Chemotherapy

Armlupeg is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Hematopoietic Subsyndrome of Acute Radiation Syndrome

Armlupeg is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).

Ennumo³

Patients with Cancer Receiving Myelosuppressive Chemotherapy

Ennumo is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Hematopoietic Subsyndrome of Acute Radiation Syndrome

Ennumo is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).

Fulphila⁴

Patients with Cancer Receiving Myelosuppressive Chemotherapy

Fulphila is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia

Udenyca⁵**Patients with Cancer Receiving Myelosuppressive Chemotherapy**

Udenyca is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Hematopoietic Subsyndrome of Acute Radiation Syndrome

Udenyca is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation.

Ziextenzo⁶**Patients with Cancer Receiving Myelosuppressive Chemotherapy**

Ziextenzo is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Hematopoietic Subsyndrome of Acute Radiation Syndrome

Ziextenzo is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation.

Nyvepria⁷**Patients with Cancer Receiving Myelosuppressive Chemotherapy**

Nyvepria is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Fylnetra⁸**Patients with Cancer Receiving Myelosuppressive Chemotherapy**

Fylnetra is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Hematopoietic Subsyndrome of Acute Radiation Syndrome

Fylnetra is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation.

Stimufend⁹**Patients with Cancer Receiving Myelosuppressive Chemotherapy**

Stimufend is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Hematopoietic Subsyndrome of Acute Radiation Syndrome

Stimufend is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation.

Compendial Use¹⁰⁻¹⁵

- Stem cell transplantation-related indications
- Prophylaxis for chemotherapy-induced febrile neutropenia in patients with solid tumors
- Hematopoietic Acute Radiation Syndrome
- Hairy cell leukemia, neutropenic fever

All other indications are considered experimental/investigational and not medically necessary.

Documentation

Primary Prophylaxis of Febrile Neutropenia

- Documentation must be provided of the member's diagnosis and chemotherapeutic regimen.
- If chemotherapeutic regimen has a low or intermediate risk of febrile neutropenia (20% and less), documentation must be provided outlining the member's risk factors that confirm the member is at high risk for febrile neutropenia.

Coverage Criteria

Prevention of Neutropenia in Cancer Patients Receiving Myelosuppressive Chemotherapy^{1-11,13,15}

Authorization of 6 months may be granted for prevention of febrile neutropenia when all of the following criteria are met :

- The requested medication will not be used in combination with other colony stimulating factors within any chemotherapy cycle.
- The member will not receive chemotherapy at the same time as they receive radiation therapy.
- The requested medication will not be administered with weekly chemotherapy regimens.
- One of the following criteria is met :
 - The requested medication will be used for primary prophylaxis in members with a solid tumor or non-myeloid malignancies who have received, are currently receiving, or will be receiving any of the following:
 - Myelosuppressive anti-cancer therapy that is expected to result in greater than 20% incidence of febrile neutropenia (FN) (See Appendix A).
 - Myelosuppressive anti-cancer therapy that is expected to result in 10 – 20% risk of FN (See Appendix B) and who are considered to be at high risk of FN because of bone marrow compromise, co-morbidities, or other patient specific risk factors (See Appendix C).
 - Myelosuppressive anti-cancer therapy that is expected to result in less than 10% risk of FN and who have at least 2 patient-related risk factors (See Appendix C).

- The requested medication will be used for secondary prophylaxis in members with solid tumors or non-myeloid malignancies who experienced a febrile neutropenic complication or a dose-limiting neutropenic event (a nadir or day of treatment count impacting the planned dose of chemotherapy) from a prior cycle of similar chemotherapy, with the same dose and scheduled planned for the current cycle (for which primary prophylaxis was not received).

Other Indications¹²⁻¹⁵

Authorization of 6 months may be granted for members with any of the following indications:

- Stem cell transplantation-related indications
- Hematopoietic Subsyndrome of Acute Radiation Syndrome
- Treatment for radiation-induced myelosuppression following a radiological/nuclear incident
- Hairy cell leukemia

Members with hairy cell leukemia with neutropenic fever following chemotherapy

Continuation of Therapy

All members (including new members) requesting authorization for continuation of therapy must meet all requirements in the coverage criteria.

Appendix^{11,15-17}

Appendix A: Selected Chemotherapy Regimens with an Incidence of Febrile Neutropenia of Greater than 20%

This list is not comprehensive; there are other agents/regimens that have an intermediate/high risk for development of febrile neutropenia.

Acute Lymphoblastic Leukemia

Select ALL regimens as directed by treatment protocol (see NCCN guidelines ALL)

Bladder Cancer

Dose dense MVAC (methotrexate, vinblastine, doxorubicin, cisplatin)

Bone Cancer

- VAIA (vincristine, doxorubicin, ifosfamide, and dactinomycin)
- VDC-IE (vincristine, doxorubicin or dactinomycin, and cyclophosphamide alternating with ifosfamide and etoposide)
- Cisplatin/doxorubicin
- VDC (cyclophosphamide, vincristine, doxorubicin or dactinomycin)
- VIDE (vincristine, ifosfamide, doxorubicin or dactinomycin, etoposide)

Breast Cancer

- Dose-dense AC (doxorubicin, cyclophosphamide) followed by dose-dense paclitaxel
- TAC (docetaxel, doxorubicin, cyclophosphamide)
- TC (docetaxel, cyclophosphamide)
- TCH (docetaxel, carboplatin, trastuzumab)

Head and Neck Squamous Cell Carcinoma

TPF (docetaxel, cisplatin, 5-fluorouracil)

Hodgkin Lymphoma

- Brentuximab vedotin + AVD (doxorubicin, vinblastine, dacarbazine)
- Nivolumab + AVD (doxorubicin, vinblastine, dacarbazine)
- Escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone)
- BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone)

Kidney Cancer

Doxorubicin/gemcitabine

Non-Hodgkin's Lymphoma

- CHP (cyclophosphamide, doxorubicin, prednisone) + brentuximab vedotin
- Dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) ± rituximab
- ICE (ifosfamide, carboplatin, etoposide) ± rituximab
- Dose-dense CHOP-14 (cyclophosphamide, doxorubicin, vincristine, prednisone) ± rituximab
- CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
- MINE (mesna, ifosfamide, mitoxantrone, etoposide) ± rituximab
- DHAP (dexamethasone, cisplatin, cytarabine) ± rituximab
- ESHAP (etoposide, methylprednisolone, cisplatin, cytarabine) ± rituximab
- HyperCVAD ± rituximab (cyclophosphamide, vincristine, doxorubicin, dexamethasone ± rituximab)
- Pola-R-CHP (polatuzumab vedotin-piiq, rituximab, cyclophosphamide, doxorubicin, prednisone)

Melanoma

Dacarbazine-based combination with IL-2, interferon alpha (dacarbazine, cisplatin, vinblastine, IL-2, interferon alfa)

Multiple Myeloma

- VTD-PACE (dexamethasone/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide + bortezomib)
- DT-PACE (dexamethasone/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide)

Ovarian Cancer

- Topotecan ± bevacizumab
- Docetaxel

- Carboplatin/docetaxel

Soft Tissue Sarcoma

- MAID (mesna, doxorubicin, ifosfamide, dacarbazine)
- Doxorubicin
- Ifosfamide/doxorubicin

Small Cell Lung Cancer

Topotecan

Testicular Cancer

- VeIP (vinblastine, ifosfamide, cisplatin)
- VIP (etoposide, ifosfamide, cisplatin)
- TIP (paclitaxel, ifosfamide, cisplatin)

Gestational Trophoblastic Neoplasia

- EMA/EP (etoposide, methotrexate, dactinomycin/etoposide, cisplatin)
- EP/EMA (etoposide, cisplatin/etoposide, methotrexate, dactinomycin)
- TP/TE (paclitaxel, cisplatin/paclitaxel, etoposide)
- BEP (bleomycin, etoposide, cisplatin)
- TIP (Paclitaxel, ifosfamide, cisplatin)
- VIP (etoposide, ifosfamide, cisplatin)
- ICE (ifosfamide, carboplatin, etoposide)

Wilms Tumor

- Regimen M (vincristine, dactinomycin, doxorubicin, cyclophosphamide, etoposide)
- Regimen I (vincristine, doxorubicin, cyclophosphamide, etoposide)
- Revised Regimen UH-1 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide)
- Revised Regimen UH-2 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, irinotecan)

Applies to chemotherapy regimens with or without monoclonal antibodies (e.g., trastuzumab, rituximab)

Appendix B: Selected Chemotherapy Regimens with an Incidence of Febrile Neutropenia of 10% to 20%

This list is not comprehensive; there are other agents/regimens that have an intermediate/high risk for development of febrile neutropenia.

Occult Primary – Adenocarcinoma

Gemcitabine/docetaxel

Breast Cancer

- Docetaxel ± trastuzumab
- AC (doxorubicin, cyclophosphamide) + sequential docetaxel (taxane portion only)
- AC + sequential docetaxel + trastuzumab
- Paclitaxel every 21 days ± trastuzumab
- Sacituzumab govitecan-hziy

- TC (docetaxel, cyclophosphamide)

Cervical Cancer

- Irinotecan
- Cisplatin/topotecan
- Paclitaxel/cisplatin ± bevacizumab
- Topotecan

Colorectal Cancer

FOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, irinotecan)

Esophageal and Gastric Cancers

Irinotecan/cisplatin

Non-Hodgkin's Lymphomas

- GDP (gemcitabine, dexamethasone, cisplatin/carboplatin)
- GDP (gemcitabine, dexamethasone, cisplatin/carboplatin) + rituximab
- CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) including regimens with pegylated liposomal doxorubicin
- CHOP + rituximab (cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) including regimens with pegylated liposomal doxorubicin
- Bendamustine

Non-Small Cell Lung Cancer

- Cisplatin/paclitaxel
- Cisplatin/vinorelbine
- Cisplatin/docetaxel
- Cisplatin/etoposide
- Carboplatin/paclitaxel
- Docetaxel

Pancreatic Cancer

FOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, irinotecan)

Prostate Cancer

Cabazitaxel

Small Cell Lung Cancer

Etoposide/carboplatin

Testicular Cancer

- BEP (bleomycin, etoposide, cisplatin)
- Etoposide/cisplatin

Uterine Sarcoma

Docetaxel

Applies to chemotherapy regimens with or without monoclonal antibodies (e.g., trastuzumab, rituximab)

Appendix C: Patient Risk Factors

This list is not all-inclusive.

- Active infections, open wounds, or recent surgery
- Age greater than or equal to 65 years
- Bone marrow involvement by tumor producing cytopenias
- Previous chemotherapy or radiation therapy
- Poor nutritional status
- Poor performance status
- Previous episodes of FN
- Other serious co-morbidities, including renal dysfunction, liver dysfunction, HIV infection, cardiovascular disease
- Persistent neutropenia

REFERENCES:

SECTION 1

1. Neulasta [package insert]. Thousand Oaks, CA: Amgen, Inc.; August 2025.
2. Fulphila [package insert]. Morgantown, WV: Mylan Pharmaceuticals, Inc.; June 2023.
3. Fylnetra [package insert]. Piscataway, NJ: Kashiv BioSciences, LLC; April 2025.
4. Nyvepria [package insert]. Lake Forest, IL: Hospira, Inc.; March 2023.
5. Rolvedon [package insert]. Irvine, CA: Spectrum Pharmaceuticals, Inc.; November 2023.
6. Stimufend [package insert]. Lake Zurich, IL: Fresenius Kabi USA, LLC; October 2025.
7. Udenyca [package insert]. Redwood City, CA: Coherus BioSciences, Inc.; December 2023.
8. Ziextenzo [package insert]. Princeton, NJ: Sandoz Inc.; February 2024.

SECTION 2

1. Neulasta [package insert]. Thousand Oaks, CA: Amgen Inc.; January 2025.
2. Armlupeg [package insert]. Naples, FL: Lupin Pharmaceuticals, Inc.; December 2025.
3. Ennumo [package insert]. Raleigh, NC: Accord BioPharma Inc.; May 2026.
4. Fulphila [package insert]. Cambridge, MA: Biocon Biologics Inc.; June 2023.
5. Udenyca [package insert]. Redwood City, CA: Coherus BioSciences, Inc.; December 2023.
6. Ziextenzo [package insert]. Princeton, NJ: Sandoz Inc.; February 2024.
7. Nyvepria [package insert]. Lake Forest, IL: Hospira, Inc.; March 2023.
8. Fylnetra [package insert]. Piscataway, NJ: Kashiv BioSciences, LLC; April 2025.
9. Stimufend [package insert]. Lake Zurich, IL: Fresenius Kabi USA, LLC; September 2023.
10. The NCCN Drugs & Biologics Compendium © 2025 National Comprehensive Cancer Network, Inc. Available at: <https://www.nccn.org> Accessed June 12, 2025.
11. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hematopoietic Growth Factors. Version 1.2025. https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf Accessed June 19, 2025.
12. IBM Micromedex® DRUGDEX® (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at <https://www.micromedexsolutions.com> (Accessed: June 19, 2025).

13. Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of white blood cell growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33(28):3199-3212.
14. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hairy Cell Leukemia. Version 1.2025. https://www.nccn.org/professionals/physician_gls/pdf/hairy_cell.pdf Accessed June 19, 2025.
15. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187-3205.
16. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Gestational Trophoblastic Neoplasia. Version 3.2025. https://www.nccn.org/professionals/physician_gls/pdf/gtn.pdf Accessed June 19, 2025.
17. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Wilms Tumor (Nephroblastoma). Version 2.2025. https://www.nccn.org/professionals/physician_gls/pdf/wilms_tumor.pdf Accessed June 19, 2025.